Novo Nordisk A/S
NYSENVO short sellers are retreating fast. Short interest in Novo Nordisk A/S dropped 29.5% over the past week to 19.9 million shares as of March 31, marking a sharp reversal in bearish positioning. The exit accelerates a monthlong trend. Shares short have fallen 37% over the past 30 days from 31.7 million shares in late January. Short sellers appear to be cutting losses as the stock climbed 7.9% over the past month, closing at $39.42 on April 21. Days to cover now sits at just 1.1, down from 1.19 a week ago and well below the 2.35 peak seen in late October. The metric indicates shorts could unwind positions quickly given current trading volumes. Cost to borrow ticked up 12.7% over the week to 0.66% APR, though it remains down 21.5% from a month ago. A brief spike to 27.4% on March 30 has since normalized. Utilization sits at just 1.81%, down from a 52-week high of 70.5%, signaling ample shares available to borrow. Options sentiment remains neutral. Put/call ratio stands at 0.71, slightly above the 20-day average of 0.71. The pharmaceutical giant reports next earnings on May 6. The data suggests short sellers are abandoning their thesis as Novo Nordisk's stock gains momentum. With utilization near historic lows and borrowing costs moderate, the crowded short that once pressured shares has largely dissipated. This is not financial advice. ORTEX data may contain errors.
Novo Nordisk Short Interest Plunges 29% in a Week
NVO short sellers are retreating fast. Short interest in Novo Nordisk A/S dropped 29.5% over the past week to 19.9 million shares as of March 31, marking a sharp reversal in bearish positioning. The exit accelerates a monthlong trend. Shares short have fallen 37% over the past 30 days from 31.7 million shares in late January. Short sellers appear to be cutting losses as the stock climbed 7.9% over the past month, closing at $39.42 on April 21. Days to cover now sits at just 1.1, down from 1.19 a week ago and well below the 2.35 peak seen in late October. The metric indicates shorts could unwind positions quickly given current trading volumes. Cost to borrow ticked up 12.7% over the week to 0.66% APR, though it remains down 21.5% from a month ago. A brief spike to 27.4% on March 30 has since normalized. Utilization sits at just 1.81%, down from a 52-week high of 70.5%, signaling ample shares available to borrow. Options sentiment remains neutral. Put/call ratio stands at 0.71, slightly above the 20-day average of 0.71. The pharmaceutical giant reports next earnings on May 6. The data suggests short sellers are abandoning their thesis as Novo Nordisk's stock gains momentum. With utilization near historic lows and borrowing costs moderate, the crowded short that once pressured shares has largely dissipated. This is not financial advice. ORTEX data may contain errors.
Snapshot as of 8 May 2026
A new long-form analysis for NVO this week — anomalies vs the company's own history, peer comparisons, news context, and the full data picture. Premium subscribers only.
Read on ORTEX →Sign up for premiumNovo Nordisk heads into its May 6 Q1 results on the back of a sharp recovery — and with the Street still broadly skeptical about what comes next. The stock has climbed 20% over the past month to $43.88, clawing back a…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for NVO — free to start on ORTEX.
